So-Young Q2 rev. down 7.4% YoY to $52.9mln, net loss widens to $5mln.
ByAinvest
Friday, Aug 15, 2025 6:11 am ET1min read
SY--
Aesthetic treatment services revenues reached RMB144.4 million (US$20.2 million), an increase of 426.1% from RMB27.4 million in the same period of 2024. This significant growth was driven by the expansion of branded aesthetic centers [1].
So-Young International reported a net loss attributable to the company of RMB36.0 million (US$5.0 million) for the quarter, compared to net income of RMB18.9 million in the same period of 2024. Non-GAAP net loss attributable to the company was RMB30.5 million (US$4.3 million), compared to non-GAAP net income of RMB22.2 million in the same period of 2024 [1].
The company's operational highlights included an aggregate value of medical aesthetic treatment transactions facilitated by its platform reaching RMB303.9 million, compared to RMB427.8 million in the same period of 2024. The number of verified treatment visits to branded aesthetic centers reached over 67,400, compared to approximately 14,000 in the same period of 2024. The number of active users exceeded 100,400, compared to approximately 16,000 users during the corresponding period in 2024 [1].
As of June 30, 2025, So-Young had 29 fully operational branded aesthetic centers in nine major cities across China, with 25 centers achieving positive monthly operating cash flow [1].
References:
[1] https://www.marketscreener.com/news/so-young-international-young-second-quarter-2025-earnings-release-ce7c51dedd89f121
• So-Young International reported Q2 2025 total revenues of RMB378.7m ($52.9m) • Aesthetic treatment services revenue reached RMB144.4m ($20.2m) • Net loss attributable to So-Young International was RMB36.0m ($5.0m) • Non-GAAP net loss attributable to So-Young International was RMB30.5m ($4.3m)
So-Young International Inc. (Nasdaq: SY), a leading aesthetic treatment platform in China, has announced its unaudited financial results for the second quarter ended June 30, 2025. The company reported total revenues of RMB378.7 million (US$52.9 million), a decrease of 7.0% from RMB407.4 million in the same period of 2024 [1]. The decrease was primarily due to a decrease in the number of medical service providers subscribing to information services on So-Young's platform.Aesthetic treatment services revenues reached RMB144.4 million (US$20.2 million), an increase of 426.1% from RMB27.4 million in the same period of 2024. This significant growth was driven by the expansion of branded aesthetic centers [1].
So-Young International reported a net loss attributable to the company of RMB36.0 million (US$5.0 million) for the quarter, compared to net income of RMB18.9 million in the same period of 2024. Non-GAAP net loss attributable to the company was RMB30.5 million (US$4.3 million), compared to non-GAAP net income of RMB22.2 million in the same period of 2024 [1].
The company's operational highlights included an aggregate value of medical aesthetic treatment transactions facilitated by its platform reaching RMB303.9 million, compared to RMB427.8 million in the same period of 2024. The number of verified treatment visits to branded aesthetic centers reached over 67,400, compared to approximately 14,000 in the same period of 2024. The number of active users exceeded 100,400, compared to approximately 16,000 users during the corresponding period in 2024 [1].
As of June 30, 2025, So-Young had 29 fully operational branded aesthetic centers in nine major cities across China, with 25 centers achieving positive monthly operating cash flow [1].
References:
[1] https://www.marketscreener.com/news/so-young-international-young-second-quarter-2025-earnings-release-ce7c51dedd89f121
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet